Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


Detection of a Tumor Suppressor Gene Variant Predisposing to Colorectal Cancer in an 18th Century Hungarian Mummy.

Feldman M, Hershkovitz I, Sklan EH, Kahila Bar-Gal G, Pap I, Szikossy I, Rosin-Arbesfeld R.

PLoS One. 2016 Feb 10;11(2):e0147217. doi: 10.1371/journal.pone.0147217. eCollection 2016.


Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.

van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M.

Gastroenterology. 2015 Nov;149(6):1425-37. doi: 10.1053/j.gastro.2015.07.042. Epub 2015 Aug 4.


Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening.

Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC.

Med Care. 2015 Jul;53(7):630-8. doi: 10.1097/MLR.0000000000000380.


The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands.

van Hees F, Zauber AG, van Veldhuizen H, Heijnen ML, Penning C, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I.

Gut. 2015 Dec;64(12):1985-97. doi: 10.1136/gutjnl-2015-309316. Epub 2015 Jun 10. Review.


Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.

Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM.

Int J Cancer. 2015 Jun 15;136(12):2864-74. doi: 10.1002/ijc.29343. Epub 2014 Dec 3.


Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina.

van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I.

Health Serv Res. 2015 Jun;50(3):768-89. doi: 10.1111/1475-6773.12246. Epub 2014 Oct 16.


The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study.

van Hees F, Zauber AG, Klabunde CN, Goede SL, Lansdorp-Vogelaar I, van Ballegooijen M.

JAMA Intern Med. 2014 Oct;174(10):1568-76. doi: 10.1001/jamainternmed.2014.3889.


Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis.

van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG.

Ann Intern Med. 2014 Jun 3;160(11):750-9. doi: 10.7326/M13-2263.


Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.

Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM.

Ann Intern Med. 2012 Nov 6;157(9):611-20. doi: 10.7326/0003-4819-157-9-201211060-00005.


Contribution of screening and survival differences to racial disparities in colorectal cancer rates.

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A.

Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):728-36. doi: 10.1158/1055-9965.EPI-12-0023. Epub 2012 Apr 18.


How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis.

Haug U, Knudsen AB, Kuntz KM.

Int J Cancer. 2012 Nov 1;131(9):2094-102. doi: 10.1002/ijc.27463. Epub 2012 Mar 29.


Five year colorectal cancer outcomes in a large negative CT colonography screening cohort.

Kim DH, Pooler BD, Weiss JM, Pickhardt PJ.

Eur Radiol. 2012 Jul;22(7):1488-94. doi: 10.1007/s00330-011-2365-2. Epub 2011 Dec 31.


Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations.

Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD.

Radiology. 2011 Nov;261(2):487-98. doi: 10.1148/radiol.11102411. Epub 2011 Aug 3.


A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression.

Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG.

Med Decis Making. 2011 Jul-Aug;31(4):530-9. doi: 10.1177/0272989X11408730. Epub 2011 Jun 14.


How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M.

Cancer. 2011 Sep 15;117(18):4166-74. doi: 10.1002/cncr.26009. Epub 2011 Mar 8.


Cost-effectiveness of colonoscopy.

Zauber AG.

Gastrointest Endosc Clin N Am. 2010 Oct;20(4):751-70. doi: 10.1016/j.giec.2010.07.008. Review.


Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis.

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M.

Ann Intern Med. 2010 Sep 21;153(6):368-77. doi: 10.7326/0003-4819-153-6-201009210-00004.


Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy.

Ladabaum U, Ferrandez A, Lanas A.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2765-76. doi: 10.1158/1055-9965.EPI-10-0530. Epub 2010 Sep 1.


Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG.

J Natl Cancer Inst. 2010 Aug 18;102(16):1238-52. doi: 10.1093/jnci/djq242. Epub 2010 Jul 27.


Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis.

Ginsberg GM, Lim SS, Lauer JA, Johns BP, Sepulveda CR.

Cost Eff Resour Alloc. 2010 Mar 17;8:2. doi: 10.1186/1478-7547-8-2.

Items per page

Supplemental Content

Support Center